Century Therapeutics (NASDAQ:IPSC) Rating Lowered to “Sell” at Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

A number of other equities research analysts have also weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised shares of Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Leerink Partners lowered shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Finally, Piper Sandler increased their price target on shares of Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Century Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $3.80.

Century Therapeutics Trading Down 5.5%

Shares of IPSC stock opened at $1.90 on Friday. Century Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.71. The company has a market capitalization of $166.06 million, a PE ratio of -5.94 and a beta of 1.72. The firm has a fifty day simple moving average of $1.23 and a 200-day simple moving average of $0.78.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Equities research analysts predict that Century Therapeutics will post -1.61 EPS for the current year.

Insider Buying and Selling

In related news, CEO Brent Pfeiffenberger purchased 52,000 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average price of $0.58 per share, with a total value of $30,160.00. Following the acquisition, the chief executive officer owned 3,322,990 shares in the company, valued at approximately $1,927,334.20. This trade represents a 1.59% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Chad Cowan bought 58,060 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was bought at an average cost of $0.85 per share, for a total transaction of $49,351.00. Following the completion of the transaction, the insider directly owned 1,045,087 shares of the company’s stock, valued at $888,323.95. This trade represents a 5.88% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 145,060 shares of company stock worth $97,011 and have sold 65,987 shares worth $29,798. 4.37% of the stock is currently owned by corporate insiders.

Institutional Trading of Century Therapeutics

Large investors have recently modified their holdings of the company. Two Sigma Investments LP grew its position in Century Therapeutics by 59.2% in the 3rd quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock worth $454,000 after purchasing an additional 338,902 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Century Therapeutics by 29.3% in the third quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock worth $301,000 after purchasing an additional 136,873 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Century Therapeutics during the second quarter valued at $248,000. Citadel Advisors LLC increased its holdings in shares of Century Therapeutics by 64.1% during the third quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock valued at $180,000 after purchasing an additional 140,891 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Century Therapeutics by 101.2% during the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares in the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.